These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 10842201

  • 21. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer.
    Miyake H, Nelson C, Rennie PS, Gleave ME.
    Cancer Res; 2000 Jan 01; 60(1):170-6. PubMed ID: 10646870
    [Abstract] [Full Text] [Related]

  • 22. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.
    van de Donk NW, Kamphuis MM, van Dijk M, Borst HP, Bloem AC, Lokhorst HM.
    Leukemia; 2003 Jan 01; 17(1):211-9. PubMed ID: 12529680
    [Abstract] [Full Text] [Related]

  • 23. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts.
    Smith MR, Jin F, Joshi I.
    Mol Cancer Ther; 2004 Dec 01; 3(12):1693-9. PubMed ID: 15634664
    [Abstract] [Full Text] [Related]

  • 24. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
    Narita S, So A, Ettinger S, Hayashi N, Muramaki M, Fazli L, Kim Y, Gleave ME.
    Clin Cancer Res; 2008 Sep 15; 14(18):5769-77. PubMed ID: 18794086
    [Abstract] [Full Text] [Related]

  • 25. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts.
    Anai S, Goodison S, Shiverick K, Hirao Y, Brown BD, Rosser CJ.
    Mol Cancer Ther; 2007 Jan 15; 6(1):101-11. PubMed ID: 17237270
    [Abstract] [Full Text] [Related]

  • 26. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
    Simões-Wüst AP, Schürpf T, Hall J, Stahel RA, Zangemeister-Wittke U.
    Breast Cancer Res Treat; 2002 Nov 15; 76(2):157-66. PubMed ID: 12452453
    [Abstract] [Full Text] [Related]

  • 27. Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment.
    Hopkins-Donaldson S, Cathomas R, Simões-Wüst AP, Kurtz S, Belyanskaya L, Stahel RA, Zangemeister-Wittke U.
    Int J Cancer; 2003 Aug 20; 106(2):160-6. PubMed ID: 12800189
    [Abstract] [Full Text] [Related]

  • 28. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
    Leonetti C, D'Agnano I, Lozupone F, Valentini A, Geiser T, Zon G, Calabretta B, Citro G C, Zupi G.
    J Natl Cancer Inst; 1996 Apr 03; 88(7):419-29. PubMed ID: 8618233
    [Abstract] [Full Text] [Related]

  • 29. Down-regulation of protein kinase Ceta by antisense oligonucleotides sensitises A549 lung cancer cells to vincristine and paclitaxel.
    Sonnemann J, Gekeler V, Ahlbrecht K, Brischwein K, Liu C, Bader P, Müller C, Niethammer D, Beck JF.
    Cancer Lett; 2004 Jun 25; 209(2):177-85. PubMed ID: 15159020
    [Abstract] [Full Text] [Related]

  • 30. p53-Independent induction of apoptosis in human melanoma cells by a bcl-2/bcl-xL bispecific antisense oligonucleotide.
    Strasberg Rieber M, Zangemeister-Wittke U, Rieber M.
    Clin Cancer Res; 2001 May 25; 7(5):1446-51. PubMed ID: 11350916
    [Abstract] [Full Text] [Related]

  • 31. Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides.
    Bolenz C, Becker A, Trojan L, Schaaf A, Cao Y, Weiss C, Alken P, Michel MS.
    Urol Oncol; 2007 May 25; 25(6):476-82. PubMed ID: 18047955
    [Abstract] [Full Text] [Related]

  • 32. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
    Tanabe K, Kim R, Inoue H, Emi M, Uchida Y, Toge T.
    Int J Oncol; 2003 Apr 25; 22(4):875-81. PubMed ID: 12632082
    [Abstract] [Full Text] [Related]

  • 33. Evaluation of cytotoxic effects induced by bcl-2 and bcl-xL antisense-oligodeoxynucleotides in normal urothelium and transitional cell carcinoma.
    Gabriel U, Bolenz C, Becker A, Schaaf A, Steidler A, Trojan L, Weiss C, Michel MS.
    Oncol Rep; 2008 Dec 25; 20(6):1419-23. PubMed ID: 19020723
    [Abstract] [Full Text] [Related]

  • 34. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.
    Zangemeister-Wittke U, Leech SH, Olie RA, Simões-Wüst AP, Gautschi O, Luedke GH, Natt F, Häner R, Martin P, Hall J, Nalin CM, Stahel RA.
    Clin Cancer Res; 2000 Jun 25; 6(6):2547-55. PubMed ID: 10873111
    [Abstract] [Full Text] [Related]

  • 35. Bcl-xL antisense oligonucleotides chemosensitize human glioblastoma cells.
    Guensberg P, Wacheck V, Lucas T, Monia B, Pehamberger H, Eichler HG, Jansen B.
    Chemotherapy; 2002 Sep 25; 48(4):189-95. PubMed ID: 12218266
    [Abstract] [Full Text] [Related]

  • 36. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
    Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI.
    Clin Cancer Res; 2003 Jul 25; 9(7):2856-65. PubMed ID: 12855666
    [Abstract] [Full Text] [Related]

  • 37. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.
    Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME.
    Neoplasia; 2001 Jul 25; 3(4):360-7. PubMed ID: 11571636
    [Abstract] [Full Text] [Related]

  • 38. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.
    Gleave M, Miyake H.
    World J Urol; 2005 Feb 25; 23(1):38-46. PubMed ID: 15770517
    [Abstract] [Full Text] [Related]

  • 39. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis.
    Fang G, Chang BS, Kim CN, Perkins C, Thompson CB, Bhalla KN.
    Cancer Res; 1998 Aug 01; 58(15):3202-8. PubMed ID: 9699642
    [Abstract] [Full Text] [Related]

  • 40. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product.
    Smythe WR, Mohuiddin I, Ozveran M, Cao XX.
    J Thorac Cardiovasc Surg; 2002 Jun 01; 123(6):1191-8. PubMed ID: 12063468
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.